


Joint Lymphoma Working Party and Cellular Therapy and Immunobiology Working Party Educational Meeting

Heidelberg, Germany | 28-30 October 2026



PRELIMINARY PROGRAMME

Wednesday, 28 October 2026
(All times in CET)

- 12:00 – 14:00 Lymphoma Working Party Scientific Business Meeting (part I)**
- 12:00 – 14:00 Cellular Therapy and Immunobiology Working Party Scientific Business Meeting**
- 14:00 – 15:00 Joint Lymphoma Working Party and Cellular Therapy and Immunobiology Working Party Scientific Business Meeting**
- 15:00 – 17:00 Lymphoma Working Party Scientific Business Meeting (part II)**
- 17:00 – 17:30 Coffee Break**
- 17:30 – 17:45 Welcome and Opening Remarks**
Ali Bazarbachi (LB), Jürgen Kuball (NL), Peter Dreger (DE)
- 17:45 – 18:30 Keynote Lecture**
Chairs: Ali Bazarbachi (LB) & Jürgen Kuball (NL)
- 17:45 - 18:30 The future of cellular therapy in lymphoma Anna Sureda (ES)


Thursday, 29 October 2026
(All times in CET)

- 08:00 – 09:30 Session I — Aggressive lymphomas**
Chairs: Bertram Glass (DE) & Ali Bazarbachi (LB)
- 08:00 - 08:20 New classifiers: does it matter for treatment Fabrice Jardin (FR)
- 08:20 - 08:40 Sequencing of cellular therapies in DLBCL (CAR, Bispes, auto, allo) Bertram Glass (DE)
- 08:40 - 09:00 Burkitt Lymphoma: current management standards and role of cellular therapy Mahmoud Aljurf (SA)
- 09:00 - 09:10 Case presentation: Multimodal treatment of EBV-positive post-transplant lymphoproliferative disease including Tabelecleucel after allogeneic hematopoietic cell transplantation Kiavasch Farid (DE)
- 09:10 - 09:30 Case and Session Discussion
- 09:30 – 10:00 Coffee Break**
- 10:00 – 11:30 Session II — Follicular lymphoma and Mantle cell lymphoma**
Chairs: Simona Pagliuca (FR) & Peter Dreger (DE)
- 10:00 - 10:20 Sequencing of cellular therapies in FL (CAR, Bispes, auto, allo) Luca Castagna (IT)
- 10:20 - 10:40 Sequencing of cellular therapies in MCL (CAR, Bispes, auto, allo) Olivier Hermine (FR)
- 10:40 - 11:00 MRD in FL and MCL: implications for prognosis and pre-emptive intervention Christiane Pott (DE)
- 11:00 - 11:10 Case presentation: Second-line brexucabtagene autoleucel for mantle cell lymphoma with rapid progression on frontline acalabrutinib-based therapy: complete metabolic response complicated by severe ICANS and concurrent embolic stroke Fernando Gibran-Nunes (BR)
- 11:10-11:30 Case and Session Discussion

For further information, please contact scientificprogramme@ebmt.org

Joint Lymphoma Working Party and Cellular Therapy and Immunobiology Working Party Educational Meeting

Heidelberg, Germany | 28-30 October 2026



PRELIMINARY PROGRAMME

Thursday, 29 October 2026 - continued
(All times in CET)

11:30 – 12:30 **Session III — New targets and microbiota**

Chairs: Alex Rampotas (UK)

- 11:30 - 11:50 New microbiota data on CAR T-cells
- 11:50 - 12:10 Development of a First-in-Class CAR-T Therapy Against Calreticulin-Mutant Neoplasms
- 12:10 - 12:20 Case presentation: Investigating the role of CAR-T cell Secretome and Extracellular Vesicles in B-Cell Aplasia
- 12:20 - 12:30 Case and Session Discussion

Henrick Poeck (DE)
Alex Rampotas (UK)

Besjana Xhahysa (IT)

12:30 – 13:30 Lunch Break

13:30 – 15:30 **Session IV — Management of CART and Autoimmune Landscape**

Chairs: Jürgen Kuball (NL) & Chara Kyriakou (UK)

- 13:30 - 13:50 CAR T activity for autoimmune diseases across EBMT centres
- 13:50 - 14:10 The landscape of immune monitoring in CAR-T cell therapy
- 14:10 - 14:30 CAR T and impact on Quality of Life
- 14:30 - 14:50 Fertility recovery and management after CAR T therapies
- 14:50 - 15:00 Case presentation: Managing CPI and CAR-T in young patient with refractory primary mediastinal diffuse large B-cell lymphoma: a case of pericarditis
- 15:00 - 15:30 Case and Session Discussion

Raffaella Greco (IT)
Simona Pagliuca (FR)
Anne Spanjaart (NL)
Giorgio Orofino (IT)

Ambra Fumagalli (IT)

15:30 – 16:00 Coffee Break

16:00 – 17:30 **Session V — CART outcome predictors and late effects**

Chairs: Jürgen Kuball (NL) & Vanderson Rocha (BR)


- 16:00 - 16:20 Prognostic Scores and outcome predictors (CAR-Hematotox, EASIX, ICAHT) in CART therapy and beyond
- 16:20 - 16:40 Frailty and eligibility criteria in CAR T recipients
- 16:40 - 17:00 Secondary malignancies from the EBMT registry
- 17:00 - 17:10 Case presentation: CAR-T-induced persistent bone marrow aplasia requiring emergency haploidentical transplantation in TP53-mutated mantle cell lymphoma with spinal and cutaneous relapse
- 17:10 - 17:30 Case and Session Discussion

Ana Alarcon (ES)
Vanderson Rocha (BR)
Isabel Sánchez-Ortega (ES)

Roberto Bono (IT)

Joint Lymphoma Working Party and Cellular Therapy and Immunobiology Working Party Educational Meeting

Heidelberg, Germany | 28-30 October 2026



PRELIMINARY PROGRAMME

Friday, 30 October 2026
(All timing in CET)

08:00 – 09:30 Session VI — T-cell lymphoma

Chairs: Gandhi Damaj (FR) & Anna Sureda (ES)

- 08:00 - 08:25 The role of autologous and allogeneic Transplantation in PTCL-NOS, nTFHL, ALCL
08:25 - 08:50 The role of autologous and allogeneic Transplantation in rare TCL (HSTL, ENKTL, EATL, MEITL, ATLL, CTCL)
08:50 - 09:00 Case presentation: Ruxolitinib-based strategies in monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL): sustained survival beyond 18 months despite multiple relapses
09:00 - 09:30 Case and Session Discussion

Norbert Schmitz (DE)
Eva Domingo (ES)
Jorge Illarramendi (FR)

09:30 – 10:00 Coffee Break

10:00 – 11:30 Session VII — Hodgkin lymphoma

Chairs: Ali Bazarbachi (LB) & Alina Tanase (RO)

- 10:00 - 10:20 Is auto-HCT needed in all RR cHL patients?
10:20 - 10:40 The role of allo-HCT in cHL in 2026
10:40 - 11:00 The role of CART Cells in RR HL
11:00 - 11:10 Case presentation: Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed/Refractory Hodgkin Lymphoma in Real-World Clinical Practice: A Single-Center Experience in Kazakhstan
11:10 - 11:30 Case and Session Discussion

Carmen Martínez (ES)
Ali Bazarbachi (LB)
Ana Carolina Caballero (ES)

Dana Sailaubekova (KZ)

11:30 – 11:45 Closing Remarks

Ali Bazarbachi (LB), Jürgen Kuball (NL), Peter Dreger (DE)